ArticleThe Journal of pediatrics2019
Sildenafil Use in Children with Pulmonary Hypertension.
Article in The Journal of pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Variable clinical and hemodynamic effect of sildenafil in extreme premature infants with bronchopulmonary dysplasia-associated pulmonary hypertension.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Sildenafil in bronchopulmonary dysplasia-associated pulmonary hypertension: developmental and translational insights.Pediatric research · 2026Review
- Inhalable Dry Powders from Lyophilized Sildenafil-Loaded Liposomes with Resveratrol or Cholesterol as a Bilayer Component.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Pharmacogenetics in pediatric cardiology.Frontiers in pediatrics · 2026Article
- Effects of sildenafil and metformin on endothelin-1 in the progression of pulmonary hypertension.Open veterinary journal · 2025Article
- The rationale of using angiotensin receptor blocker instead of pulmonary vasodilators to treat pulmonary hypertension in bronchopulmonary dysplasia: a case report and literature review.Frontiers in pediatrics · 2025Article
- An interdisciplinary consensus approach to pulmonary hypertension in developmental lung disease.The European respiratory journal · 2024Review
- Kids Mod PAH trial: A multicenter trial comparing mono- versus duo-therapy for initial treatment of pediatric pulmonary hypertension.Pulmonary circulation · 2023Article
- Bronchopulmonary dysplasia - associated pulmonary hypertension: An updated review.Seminars in perinatology · 2023Review
- Combination therapy of doxorubicin and Sildenafil inhibits the growth of pediatric rhabdomyosarcoma.Journal of cancer research and clinical oncology · 2023Article
- A Non-Systemic Phosphodiesterase-5 Inhibitor Suppresses Colon Proliferation in Mice.International journal of molecular sciences · 2023Article
- Intravenous sildenafil for treatment of early pulmonary hypertension in preterm infants.Scientific reports · 2023Article
- Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Safety and Efficacy of Sildenafil for Group 2 Pulmonary Hypertension in Left Heart Failure.Children (Basel, Switzerland) · 2023Article
- Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization.Pharmaceutics · 2022Article
- Diagnosis and management of pulmonary hypertension in infants with bronchopulmonary dysplasia: a guide for paediatric respiratory specialists.Breathe (Sheffield, England) · 2022Review
- Successful treatment of pulmonary hypertension in a neonate with bronchopulmonary dysplasia: A case report and literature review.World journal of clinical cases · 2022Article
- Imaging in neonatal respiratory disease.Paediatric respiratory reviews · 2022Review
- Unique Pulmonary Hypertension in Young Children: A Case Series Study.Children (Basel, Switzerland) · 2022Article
Corrections and comments
- Commented on by
- Commented on byReply.2019
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess the demographics, treatment algorithm, and outcomes in a large cohort of children treated with sildenafil. STUDY
designA retrospective cohort study of children with pulmonary hypertension (PH) treated with sildenafil at a single institution between 2004 and 2015. Baseline and follow-up data collected by chart review.
resultsThere were 269 children included in this study: 47 with idiopathic pulmonary arterial hypertension, 53 with congenital heart disease, 135 with bronchopulmonary dysplasia, 24 with congenital diaphragmatic hernia, and 7 with other causes. Sildenafil was initial monotherapy in 84.8% and add-on therapy in 15.2%. Median follow-up time was 3.1 years (2 weeks-12.4 years). On follow-up, 99 (37%) remained on sildenafil or transitioned to tadalafil, 93 (35%) stopped sildenafil for improvement in PH, 54 (20%) died, and 20 (7%) were lost to follow-up. PH was most likely to improve in those with bronchopulmonary dysplasia, allowing for the discontinuation of sildenafil in 45%. Eighteen deaths were related to PH and 36 from other systemic causes. Two patients stopped sildenafil owing to airway spasm with desaturation. Overall survival was significantly lower in World Health Organization group 3 PH (bronchopulmonary dysplasia and congenital diaphragmatic hernia) vs group 1 (idiopathic pulmonary arterial hypertension and congenital heart disease), P = .02.
conclusionsIn this retrospective experience in children with mainly World Health Organization groups 1 and 3 PH, low-dose sildenafil was well-tolerated, safe, and had an acceptable side effect profile. Although patients with group 3 PH have high mortality, survivors have a high likelihood of PH improving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.